Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep is now Phase 3-ready

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 05, 2023 9:18am

154 Views

Post# 35480090

RE:RE:ONCY's pelareorep is now Phase 3-ready

Dr. Martine J. Piccart, M.D., Ph.D stated that a two-arm registration study in metastatic breast cancer is more practical and less expensive than a three arm study which would otherwise include an immune checkpoint inhibitor. Having pelareorep approved for metastatic breast cancer with paclitaxel would also offer the treatment to a wider base of breast cancer patients than otherwise.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand